Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2024—A “grimoire” for laboratories—that’s what J. Mark Tuthill, MD, of Henry Ford Health was asked to talk about at the Pathology Informatics Summit in May. Once he learned what the term meant, he got to work, and his book of magic for laboratories unfolded. He did not use a large language model to create his spells because “only a wizard” can teach such things, he said, which is why he consulted his 11-year-old grandson.
September 2024—Tried and true but also having untapped potential is how three industry insiders see urinalysis. Though traditional urinalysis serves its purpose well, they say, it’s easy to envision the next level. “We tend to look at urinalysis with a fairly myopic view of counting particles and doing a dipstick,” says Jason Anderson, MPH, MT(ASCP), senior product manager for urinalysis solutions, Sysmex America. “So what becomes the definition of urinalysis in the future?” he asks. “When we look at blood, it isn’t plasma analysis, it isn’t serum analysis. It’s specific disease conditions, disciplines that use that fluid type. So I see urinalysis becoming a broader field in a sense that there has been a lack of research in urinalysis in general for some time and there’s huge capacity in a urine sample and an unmet need for better biomarkers.” This need, he says, spans the spectrum of diseases, not just renal diseases. “And those biomarkers, those metabolites, that are potentially useful in diagnosing various conditions can be found in urine.”
September 2024—New cancer surveillance standards for tumor site, histology, and behavior code combinations and associated terms rolled out this year, after pathologists reviewed the combinations in an all-new effort. It’s an initiative known as Cancer PathCHART, short for Cancer Pathology Coding Histology and Registration Terminology, led by the National Cancer Institute with the support of 10 collaborating organizations, among them the CAP and the World Health Organization. “Nobody but the NCI could’ve done this. It’s been a great project,” says Kay Washington, MD, PhD, professor of pathology at Vanderbilt University Medical Center and a past member of the CAP Cancer Committee and American Joint Committee on Cancer.
September 2024—The barriers to using sustainable practices in a clinical laboratory are legion: too much work and too little time, space, infrastructure, awareness, and education. And the waste streams for biohazardous and chemical hazardous material are complex. It’s therefore challenging to advise how to get a sustainability program going, which is why Joe Wiencek, PhD, D(ABCC), says, “Starting somewhere, anywhere, is half the battle.” When the European Federation of Clinical Chemistry and Laboratory Medicine issued its guidelines in 2022 for green and sustainable medical labs, its focus was on chemicals, energy, waste, and water. Waste has been the focus of research in the clinical labs at Vanderbilt University Medical Center, where Dr. Wiencek is service line medical director of the core laboratory, medical director of clinical chemistry, and associate professor of pathology, microbiology, and immunology.
September 2024—The use of artificial intelligence in medicine is spreading rapidly, but it’s not entirely new. Tools that incorporate AI have been approved by the FDA since the mid-1990s, mostly for use in radiology and cardiology. Like all of our colleagues in medicine, we pathologists have been hearing a lot about AI lately. Some of us are excited about it, and most of us are familiar with the surge of hype claiming that AI will change everything about how we practice.
September 2024—Syphilis, an infectious disease caused by the spirochete bacterium Treponema pallidum, can be transmitted by blood transfusion. Therefore, donor blood has been routinely screened for syphilis since the 1950s. Although a case of transfusion-transmitted syphilis has not been documented in more than 50 years, routine serological testing is still performed because there is not sufficient evidence that it is no longer necessary. Syphilis testing can contribute to disease monitoring for overall public health by identifying infected blood donors so they can seek treatment to prevent further spread. The Transfusion Transmissible Infections Monitoring System (TTIMS) monitors infectious disease and demographic changes in donors who contribute approximately 60 percent of the U.S. blood supply, including at four major blood-collection organizations.
September 2024—Research has shown assessment of tumor-associated stroma to be of reliable prognostic value. The authors conducted a study in which they evaluated the prognostic value of tumor-stroma ratio in a large multicenter cohort of nasopharyngeal carcinoma. They used the conventional H&E-stained slides of 115 cases of nasopharyngeal carcinoma to assess tumor-stroma ratio as described in recent guidelines. The amount of tumor-associated stroma was assessed as a percentage and then tumors were classified as stroma high (more than 50 percent) or stroma low (50 percent or less). Kaplan-Meier curves, a χ2 test, and Cox regression univariable and multivariable analyses were conducted.
September 2024—Oncology patients may benefit greatly from whole genome sequencing. Previous studies have suggested that it can provide relevant information pertaining to pediatric cancers, especially in selected cohorts of patients with high-risk disease. However, its clinical utility has not been thoroughly explored in routine clinical practice. The authors of this study examined the benefits of whole genome sequencing (WGS) in a consecutive cohort of pediatric patients from two institutions who required molecular workup for hematological neoplasms and solid tumors. Great Ormond Street Hospital, London, and Cambridge (England) University Hospitals offered WGS to patients with leukemia or solid tumors, respectively.
September 2024
Q. When performing body fluid cell counts, we report total nucleated cells and RBCs. What cell categories should we report on the corresponding differential? Can we group together monocytes, macrophages, and mesothelial cells since it is difficult to distinguish reactive mesothelial cells from monocytes and macrophages? If so, what category name should be applied? Should we report mesothelial cells as a comment or include them in the differential? Read answer.
Q. Are nonlaboratory personnel who perform point-of-care testing required to be tested for visual color discrimination? Or is it sufficient that personnel pass a functional assessment during their competency evaluation to evaluate their ability to provide an accurate result on tests that require interpreting colors? Read answer.
September 2024—The ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine has created the Sherrie Perkins Research and Innovation Collaboration grant to fund lab medicine research that has the potential to significantly improve patient care.
